Uncategorized
Text Mining Culture Conditions and Glycosylation Relationships
A novel data gathering approach that relies on “text mining” can help process developers better understand the complex relationships between culture conditions and glycosylation, say the authors of new research.
A protein’s glycosylation profile—the pattern of glycan residues that bind to the core molecule during production—dictates its therapeutic function and efficacy. A reproducible profile is key to achieving quality and consistency goals.
And, for the most part, biopharma is good at using experimentation to understand how changes to culture conditions are likely to impact glycosylation processes for a given developmental manufacturing process.
Industry has been less adept at using these experimental findings to develop generalized glycosylation relationship models, says Chuming Chen, PhD, a professor at the Delaware Biotechnology Institute at the University of Delaware.
“Despite the extensive body of published work, general relationships between different cell culture conditions and glycosylation profiles remain fragmented across diverse studies. Fragmentation in our knowledge of causes of specific glycan profiles is partially a result of variables and conditions changing from one context to another, and these are not always easily tracked,” he tells GEN.
Test mining and knowledge graphs
With this in mind, Chen, colleagues, and scientists at Waters who co-authored the study, developed an automated way of gathering data from multiple sources—using a technique called “text mining”—and elucidating relationships between various conditions and glycosylation.
“First, we designed a specialized text mining pipeline to automatically extract relationships between cell culture conditions and glycosylation profiles with an 88% accuracy from unstructured scientific literature, eliminating the need for manual curation,” Chen explains.
The researchers then used a normalization strategy to reconcile inconsistencies in the extracted information to ensure consistency.
“These standardized entities and the relationships among them were used to build a unified Knowledge Graph [called the Bioprocess Knowledge Graph Database], which captures both direct and hidden, indirect associations between process parameters and therapeutic glycan outcomes.
“Finally, we developed a web interface that enables researchers to dynamically query, explore, and visualize these complex relationships, ultimately facilitating more informed decision-making in therapeutic protein manufacturing,” he says.
The approach has application in biopharmaceutical manufacturing, according to Chen, who suggests it can be used to guide early-phase process development.
“The benefit to biopharmaceutical manufacturing process researchers is to identify specific contexts and conditions that may increase or decrease the target glycan structure. Because glycan structure can sometimes impact the mechanism of action or drug-patient interactions, this can be highly useful information,” he adds.
Looking forward, Chen and his co-authors plan to expand their system to include more information that is relevant to production.
“Our final product is an interface that is queryable and visualizable. Although it has been developed as a prototype, this is automated and can be extended to incorporate more information related to biopharmaceutical manufacturing. We are currently extending our project to include deep learning and LLM for relation extraction,” he says.
The post Text Mining Culture Conditions and Glycosylation Relationships appeared first on GEN – Genetic Engineering and Biotechnology News.
Uncategorized
BioNTech to shutter Singapore HQ after ‘comprehensive review’
BioNTech, in a move to streamline its operations, is set to close its factory in Singapore that it bought from Novartis just over three years ago.
The facility at the Tuas Biomedical Park, which employs …
Uncategorized
STAT+: Merck’s experimental HIV prevention pill could be made for less than $5 a year, researchers say
An experimental HIV prevention pill being developed by Merck could be mass produced for less than $5 per patient a year according to a new analysis. Advocates argue the low cost means the company should find it easier to license the drug so that low- and middle-income countries can gain easy access.
The pill, dubbed MK 8527, is currently undergoing a pair of late-stage clinical trials that are expected to determine whether the medicine can lower HIV transmission when given to people at high risk of infection. The results are due in the latter half of 2027, according to ClinicalTrials.gov.
Already, the pill is generating considerable interest after Merck released mid-stage results last summer showing its drug holds promise. In addition to being safe and effective, the study found it could protect against infection, a form of prevention known as pre-exposure prophylaxis or PrEP, within 24 hours after being taken. Merck noted the pill works in a novel way.
An experimental HIV prevention pill being developed by Merck could be mass produced for less than $5 per patient a year according to a new analysis. Advocates argue the low cost means the company should find it easier to license the drug so that low- and middle-income countries can gain easy access.
The pill, dubbed MK 8527, is currently undergoing a pair of late-stage clinical trials that are expected to determine whether the medicine can lower HIV transmission when given to people at high risk of infection. The results are due in the latter half of 2027, according to ClinicalTrials.gov.
Already, the pill is generating considerable interest after Merck released mid-stage results last summer showing its drug holds promise. In addition to being safe and effective, the study found it could protect against infection, a form of prevention known as pre-exposure prophylaxis or PrEP, within 24 hours after being taken. Merck noted the pill works in a novel way.
Uncategorized
Opinion: STAT+: Former Geisinger CEO: U.S. health systems must replace huge numbers of people with AI
About 20 years ago, I stepped on stage at one of our Geisinger town halls and looked out upon a sea of people: thousands of full-time employees at an integrated health system charged with the health and well-being of millions of Pennsylvanians.
Only a fraction of the people in that room were clinicians.
That was the first time I fully visualized the problem: We employed more people in our revenue cycle department to process bills and reconcile data than we did doctors. And we weren’t alone. It’s the same story at every health system in America, large and small, and over the past two decades, the ratio has become dramatically more disparate.
About 20 years ago, I stepped on stage at one of our Geisinger town halls and looked out upon a sea of people: thousands of full-time employees at an integrated health system charged with the health and well-being of millions of Pennsylvanians.
Only a fraction of the people in that room were clinicians.
That was the first time I fully visualized the problem: We employed more people in our revenue cycle department to process bills and reconcile data than we did doctors. And we weren’t alone. It’s the same story at every health system in America, large and small, and over the past two decades, the ratio has become dramatically more disparate.
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Contributors9 years agoThe final 6 ‘Game of Thrones’ episodes might feel like a full season
-
Uncategorized9 years agoAccording to Dior Couture, this taboo fashion accessory is back
-
Uncategorized9 years agoThe old and New Edition cast comes together to perform
-
Uncategorized9 years agoPhillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years agoUber and Lyft are finally available in all of New York State
-
Uncategorized9 years agoDisney’s live-action Aladdin finally finds its stars
-
Uncategorized9 years agoSteph Curry finally got the contract he deserves from the Warriors